PT2254570E - Combinação que compreende paclitaxel para o tratamento de cancro de ovário - Google Patents

Combinação que compreende paclitaxel para o tratamento de cancro de ovário Download PDF

Info

Publication number
PT2254570E
PT2254570E PT97123343T PT09712334T PT2254570E PT 2254570 E PT2254570 E PT 2254570E PT 97123343 T PT97123343 T PT 97123343T PT 09712334 T PT09712334 T PT 09712334T PT 2254570 E PT2254570 E PT 2254570E
Authority
PT
Portugal
Prior art keywords
paclitaxel
combination
ovarian cancer
treating ovarian
treating
Prior art date
Application number
PT97123343T
Other languages
English (en)
Inventor
Martine Clozel
Urs Regenass
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40670930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2254570(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of PT2254570E publication Critical patent/PT2254570E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97123343T 2008-02-20 2009-02-19 Combinação que compreende paclitaxel para o tratamento de cancro de ovário PT2254570E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2008050607 2008-02-20

Publications (1)

Publication Number Publication Date
PT2254570E true PT2254570E (pt) 2014-02-17

Family

ID=40670930

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97123343T PT2254570E (pt) 2008-02-20 2009-02-19 Combinação que compreende paclitaxel para o tratamento de cancro de ovário

Country Status (19)

Country Link
US (2) US8541433B2 (pt)
EP (1) EP2254570B1 (pt)
JP (1) JP5514123B2 (pt)
KR (1) KR20100132489A (pt)
CN (1) CN101939001B (pt)
AR (1) AR070456A1 (pt)
AU (1) AU2009215329B2 (pt)
CA (1) CA2714608A1 (pt)
CY (1) CY1115071T1 (pt)
DK (1) DK2254570T3 (pt)
ES (1) ES2446303T3 (pt)
HR (1) HRP20140215T1 (pt)
MX (1) MX2010008994A (pt)
PL (1) PL2254570T3 (pt)
PT (1) PT2254570E (pt)
RU (1) RU2494736C2 (pt)
SI (1) SI2254570T1 (pt)
TW (1) TWI441639B (pt)
WO (1) WO2009104149A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615898B8 (pt) 2005-09-12 2021-05-25 Actelion Pharmaceuticals Ltd composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
JP5514123B2 (ja) * 2008-02-20 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド 卵巣癌を治療するための、パクリタキセルを含む配合剤
NZ591601A (en) 2008-08-13 2012-12-21 Actelion Pharmaceuticals Ltd Therapeutic compositions containing macitentan and a prostacyclin receptor agonist
PL2464218T3 (pl) 2009-08-10 2015-12-31 Univ Texas Leczenie przerzutów do mózgu z zastosowaniem inhibitorów receptorów endoteliny w skojarzeniu z cytotoksycznym środkiem chemioterapeutycznym
KR101563069B1 (ko) * 2011-02-04 2015-10-23 액테리온 파마슈티칼 리미티드 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
CN103819411A (zh) * 2014-03-14 2014-05-28 成都克莱蒙医药科技有限公司 一种马西替坦中间体新的制备方法
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
DE60118782T2 (de) * 2000-12-18 2007-01-25 Actelion Pharmaceuticals Ltd. Neue sulfamiden und deren verwendung als endothelin-antagonisten
WO2004037235A2 (en) * 2002-10-24 2004-05-06 The Board Of Trustees Of The University Of Illinois Method and composition for preventing and treating solid tumors
US20040121971A1 (en) 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
BRPI0615898B8 (pt) 2005-09-12 2021-05-25 Actelion Pharmaceuticals Ltd composição farmacêutica, e, uso de um composto ou de um sal, um solvato, um hidrato ou uma forma morfológica do mesmo farmaceuticamente aceitável
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
JP5514123B2 (ja) * 2008-02-20 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド 卵巣癌を治療するための、パクリタキセルを含む配合剤
KR20100005486A (ko) * 2008-07-07 2010-01-15 페어차일드코리아반도체 주식회사 스위치 제어 장치 및 이를 포함하는 컨버터

Also Published As

Publication number Publication date
HRP20140215T1 (hr) 2014-04-11
WO2009104149A1 (en) 2009-08-27
AR070456A1 (es) 2010-04-07
JP5514123B2 (ja) 2014-06-04
CA2714608A1 (en) 2009-08-27
US20130317048A1 (en) 2013-11-28
SI2254570T1 (sl) 2014-03-31
EP2254570B1 (en) 2013-12-18
CY1115071T1 (el) 2016-12-14
CN101939001A (zh) 2011-01-05
CN101939001B (zh) 2012-06-20
DK2254570T3 (da) 2014-02-03
TW200940062A (en) 2009-10-01
TWI441639B (zh) 2014-06-21
RU2010138650A (ru) 2012-03-27
MX2010008994A (es) 2010-09-07
US20100311774A1 (en) 2010-12-09
KR20100132489A (ko) 2010-12-17
AU2009215329A1 (en) 2009-08-27
RU2494736C2 (ru) 2013-10-10
EP2254570A1 (en) 2010-12-01
US8541433B2 (en) 2013-09-24
PL2254570T3 (pl) 2014-05-30
AU2009215329B2 (en) 2014-08-21
ES2446303T3 (es) 2014-03-07
JP2011512399A (ja) 2011-04-21

Similar Documents

Publication Publication Date Title
HK1200363A1 (en) Compounds useful for treating cancer
EP2310006A4 (en) TREATMENT OF CANCER
HK1131577A1 (en) Compositions for treating cancer
IL209895A0 (en) Compounds for treating beta-amyloidoses
EP2303021A4 (en) COMPOUNDS FOR TREATING CANCER
IL213398A0 (en) Compounds for treating cancer
EP2424516A4 (en) PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER
ZA201003123B (en) Thiazol derivavtives for treating cancer
SI2254570T1 (sl) Kombinacija, obsegajoča paklitaksel, za zdravljenje raka na jajčnikih
ZA201203449B (en) Sulfoxide derivatives for treating tumors
EP2144888A4 (en) METHODS OF TREATING CANCER
GB0804496D0 (en) Treating cancer
EP2210099A4 (en) BIOMARKER FOR OVARIAL CARCINOMA
SI2467140T1 (sl) Lapatinib za zdravljenje raka
EP2068911A4 (en) METHOD FOR THE TREATMENT OF CANCER
EP2473506A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER
EP2281575A4 (en) ANTIBODIES FOR THE TREATMENT OF CANCER
GB0707556D0 (en) Treatment for cancer
EP2307573A4 (en) METHODS FOR SCREENING COMPOUNDS FOR TREATING CANCER
GB0809046D0 (en) Cancer treatment
EP2319873A4 (en) DEXTRAN TO TREAT LUNG CANCER
GB0914322D0 (en) Compounds for treating cancer
GB0808116D0 (en) bioarker for pancreatic cancer
GB0619271D0 (en) Treating cancer
GB0722030D0 (en) Compositions for treating tumours